Creatine for Perimenopause: What the Evidence Does and Does Not Show

Perimenopause is not the sample in the 2026 pool

The review people will hand you is creatine monohydrate for lean mass, strength, and bone density in postmenopausal women (Journal of the International Society of Sports Nutrition, 2026). Seven randomized, placebo-controlled trials, 608 women randomized, durations from 12 to 104 weeks. Mean age was about 62, and the study mean ages ran from 57 to 70. Lean mass favored creatine by 0.37 kg (95% confidence interval 0.05 to 0.69) in the five trials pooled for that outcome. Leg press favored creatine by 7.5 kg (95% confidence interval 2.2 to 12.8) in three trials. Bone mineral density did not improve overall. Adverse events were described as mild and similar to placebo, and renal indices were unchanged.

Read the population line in the paper, not the social caption. The trials enrolled postmenopausal women. The authors wrote that none of the trials focused on menopause specifically, although one trial included a small fraction of women they described as perimenopausal, within five years of menopause. They did not publish that fraction as its own result. Using the 0.37 kg figure as a perimenopause promise skips the age and the menstrual status of the sample.

The postmenopausal numbers, including the bone-geometry findings that did not change density, are unpacked on creatine and menopause. Product picks aimed at women over 50 are on best creatine for women over 50.

What the cycle review hypothesized

Smith-Ryan and colleagues (2021) argued that estrogen and progesterone change creatine synthesis, transport, and creatine kinase activity, so supplementation might matter during menses, pregnancy, postpartum, and the menopause transition. They cite animal work on the enzyme that limits creatine synthesis, and they note serum creatine kinase running higher during menstruation than in non-menstruating years. They also place a high-estrogen window in the luteal phase and suggest creatine might be more useful then because protein breakdown is higher and carbohydrate storage is lower.

That is a mechanism paper's invitation. It is not a randomized trial that assigned perimenopausal women to creatine or placebo and counted hot flashes, cycle length, or hip density. The phrase in their abstract, "may be particularly important," is the authors' judgment of a gap. We are leaving it as a hypothesis.

Premenopausal training trials inside that same review are a different bucket. Vandenberghe and colleagues, as Smith-Ryan summarizes them, saw muscle phosphocreatine rise about 6% after four days at 20 grams a day in sedentary women, then higher strength than placebo across 10 weeks of training at 5 grams a day. Eckerson and colleagues, again via that review, reported about a 22% rise in anaerobic working capacity after five days at 20 grams a day in physically active women. Ferguson and Syrotuik, in physically active women ages 18 to 35, did not find extra strength or lean mass from 10 weeks of creatine plus training compared with training alone. Young-adult results do not become a perimenopause result by waiting a decade.

Muscle, bone, and mood, without borrowing the wrong age

The strongest postmenopausal pattern in the 2026 pool showed up when the dose was at least 5 grams a day and the women lifted. Trials at 3 grams a day or less, without resistance training, did not show a measurable lean-mass benefit. If you are still having cycles and you lift, the habit that matches the later-life trials is resistance training plus a real daily dose, not a creatine capsule in place of the gym. The dose page is the dosing guide.

Bone density is the claim to be careful with. The 2026 pool found no overall bone-density benefit in postmenopausal women. Fracture risk was not an endpoint. A perimenopause bone claim would be a further step past a null density result in older women. We will not take that step.

Mood is the other borrow. Smith-Ryan notes that depression is more common at hormonal milestones, including perimenopause, and reviews early creatine research on brain energy. Our brain page, creatine for the brain, keeps those trials in their own lane: small effects, clearer in older adults in the summaries we use, not a treatment for perimenopausal depression. If mood is the reason you are here, talk to a clinician. A powder is not a substitute for that visit.

A practical dose while the perimenopause trials do not exist

Three to five grams of creatine monohydrate a day, on lifting days and on days you do not lift, is the maintenance range from the 2017 ISSN position stand. Smith-Ryan's review mentions short high-dose loading, around 0.3 grams per kilogram per day, in some postmenopausal function studies. That is a loading-style week in older women, not a permanent perimenopause prescription, and it is not what we hand someone whose main issue is a changing cycle.

Skip the loading week if your stomach is new to the powder. The 30-day version is how to take creatine. The clock on water weight versus strength is how long creatine takes to work. Before versus after training is creatine timing. A first tub is creatine for women beginners.

Women over 40 who want a product list, not a trial table, can use best creatine for women over 40. The safety boundaries, including pregnancy, are on creatine side effects in women. Strength, lean mass, and bone, kept as separate measurements, are on creatine benefits for women.

What we still do not know about perimenopause

We do not have a randomized trial that recruited women in perimenopause, held the rest of the program steady, and measured muscle, bone, cycle symptoms, and side effects against placebo. The 2026 review itself was not prospectively registered, and the authors rated most included trials as having some risk-of-bias concerns. One large preregistered trial in that pool was at low risk, and it was still a postmenopausal sample.

Hormone therapy, thyroid disease, and antidepressants change the question again. Nothing on this page tells you to start or stop a prescription. If you want the studied postmenopausal record before you decide the gap is the whole story, read the menopause evidence next.

Common questions

Sources

• Creatine monohydrate for lean mass, strength, and bone density in postmenopausal women: a systematic review and meta-analysis. J Int Soc Sports Nutr. 2026. Used for seven trials, 608 women, mean age about 62, lean mass +0.37 kg, leg press +7.5 kg, no overall bone-density effect, and the note that the trials were postmenopausal with only a small perimenopausal fraction in one trial.
• Smith-Ryan AE, et al. 2021. Creatine supplementation in women's health: a lifespan perspective. Nutrients. Used for the cycle hypothesis, the luteal-phase discussion, the Vandenberghe and Eckerson summaries, and the Ferguson null result in women 18 to 35.
• Kreider RB, et al. 2017. ISSN position stand. Used for the 3 to 5 g maintenance range.

Editorial note: This page is informational and does not provide personalized medical advice. Study findings describe groups, not guarantees for individuals. If you have a medical condition, take prescription medication, are pregnant, or have symptoms that concern you, discuss supplement use with a qualified clinician.